Neoadjuvant Cisplatin, Epirubicin, and Capecitabine vs Cisplatin and Fluorouracil for Esophageal Cancer
Categories
Neoadjuvant chemotherapy with epirubicin, cisplatin, and capecitabine (ECX) does not improve survival compared with cisplatin and fluorouracil (CF) among patients with esophageal cancer, according to a study published in The Lancet Oncology.1
http://www.cancertherapyadvisor.com/gastrointestinal-cancers/esophageal-cancer-neoadjuvant-cisplatin-epirubicin-capecitabine-vs-cisplatin-fluorouracil/article/680267/